Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.

Published on Sep 23, 2017in Biochemical and Biophysical Research Communications2.985
· DOI :10.1016/J.BBRC.2017.07.148
Naoki Hamada15
Estimated H-index: 15
(Kyushu University),
Toyoshi Yanagihara9
Estimated H-index: 9
(Kyushu University)
+ 5 AuthorsYoichi Nakanishi64
Estimated H-index: 64
(Kyushu University)
Sources
Abstract
Abstract Although several antibodies developed to target programmed cell death-1 (PD-1) and its ligand (PD-L1) have demonstrated great promise for the treatment of non-small cell lung cancer (NSCLC), and other malignancies, these therapeutic antibodies can cause pneumonitis. Furthermore, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-induced pneumonitis was reported after treatment with anti PD-1 antibodies. We previously demonstrated that mice with naphthalene-induced airway epithelial injury developed severe gefitinib-induced pneumonitis through a neutrophil-dependent mechanism. The present study aimed to investigate whether treatment with afatinib, an EGFR-TKI that effectively targets EGFR mutation-positive NSCLC, and anti PD-1 antibodies induces pneumonitis in mice. C57BL/6J mice were treated intraperitoneally with naphthalene (200 mg/kg) on day 0. Afatinib (20 mg/kg) was administered orally on days −1 to 13. An anti-PD-1 antibody (0.2 mg/mice) was also administered intraperitoneally every 3 days from day 1 until day 13. The bronchoalveolar lavage fluid (BALF) and lung tissues were sampled on day 14. As observed previously with gefitinib, afatinib significantly increased the severity of histopathologic findings and the level of protein in BALF on day 14, compared to treatment with naphthalene alone. A combined anti-PD-1 antibody and afatinib treatment after naphthalene administration had yielded the same histopathological grade of lung inflammation as did afatinib treatment alone. Our results suggest that anti-PD-1 antibody treatment has little effect on afatinib-induced lung injury.
📖 Papers frequently viewed together
2 Citations
1 Citations
29 Citations
References24
Newest
#1Hironori Mikumo (Kyushu University)H-Index: 4
#2Toyoshi Yanagihara (Kyushu University)H-Index: 9
Last. Yoichi Nakanishi (Kyushu University)H-Index: 64
view all 10 authors...
Abstract Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is an effective therapeutic agent for non-small cell lung cancer with EGFR mutations. It can cause severe acute pneumonitis in some patients. We previously demonstrated that mice with naphthalene-induced airway epithelial injury developed severe gefitinib-induced pneumonitis and that neutrophils played important roles in the development of the disease. This study aimed to investigate the effects of the ...
7 CitationsSource
#1Jie FuH-Index: 5
#2Fang WangH-Index: 3
Last. Hai-feng SongH-Index: 1
view all 13 authors...
Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody
26 CitationsSource
#1Jarushka Naidoo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 33
#2Xuan Wang (USYD: University of Sydney)H-Index: 15
Last. Matthew D. Hellmann (Cornell University)H-Index: 77
view all 29 authors...
PurposePneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described.MethodsPatients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia:...
471 CitationsSource
#1Mie KotakeH-Index: 6
#1Mie KotakeH-Index: 2
Last. T Takahashi (Yokohama College of Pharmacy)H-Index: 1
view all 5 authors...
26 CitationsSource
#1Kazutaka Fujita (University of Tsukuba)H-Index: 2
#1Kazutaka Fujita (University of Tsukuba)H-Index: 3
Last. Nobuyuki Hizawa (University of Tsukuba)H-Index: 51
view all 9 authors...
3 CitationsSource
#1Nobuaki MamesayaH-Index: 5
#2Hirotsugu KenmotsuH-Index: 28
Last. Toshiaki TakahashiH-Index: 42
view all 6 authors...
We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20. The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) following treatment with nivolumab, an anti-Programmed Cell Death 1 (anti-PD1) antibody. After initiating osimertinib treatment, the patient began to complain of low-grade fever and shortness...
29 CitationsSource
#1Mizuki Nishino (Brigham and Women's Hospital)H-Index: 58
#2Nikhil H. Ramaiya (Brigham and Women's Hospital)H-Index: 50
Last. F.S. Hodi (Harvard University)H-Index: 21
view all 10 authors...
Purpose: Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor-related pneumonitis in advanced cancer patients. Experimental Design: Among patients with advanced melanoma, lung cancer, or lymphoma treated in trials of nivolumab, we identified those who developed pneumonitis. Chest CT scans were reviewed to assess extent, distribution, and radiographic patterns of pneumonitis. Results: Among 170 patients treated in 10 different trials of nivolumab...
239 CitationsSource
#1Mizuki Nishino (Brigham and Women's Hospital)H-Index: 58
#2Anita Giobbie-Hurder (Harvard University)H-Index: 59
Last. F. Stephen Hodi (Brigham and Women's Hospital)H-Index: 126
view all 5 authors...
Importance Programmed cell death 1 (PD-1) inhibitor–related pneumonitis is a rare but clinically serious and potentially life-threatening adverse event. Little is known about its incidence across different tumor types and treatment regimens. Objective To compare the incidence of PD-1 inhibitor–related pneumonitis among different tumor types and therapeutic regimens. Data Sources A PubMed search through November 10, 2015, and a review of references from relevant articles. For the PubMed search, t...
329 CitationsSource
#1Sang Hoon Yoo (Catholic University of Korea)H-Index: 1
#2Jin Ah Ryu (Catholic University of Korea)H-Index: 1
Last. Young Jun Yang (Catholic University of Korea)H-Index: 6
view all 10 authors...
Afatinib is an oral tyrosine kinase inhibitor (TKI) that inhibit Endothelial Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. The common side effects of EGFR TKI are rash, acne, diarrhea, stomatitis, pruritus, nausea, and loss of appetite. Drug induced pneumonitis is the less common adverse effects of EGFR TKI. Afatinib, 2nd generation EGFR TKI is anticipated to overcome drug resistance from 1st generation EGFR TKI according to preclinical study, and seve...
7 CitationsSource
#1Myung-Ju Ahn (SMC: Samsung Medical Center)H-Index: 80
#2James Chih-Hsin Yang (NTU: National Taiwan University)H-Index: 135
Last. Geoffrey R. Oxnard (Harvard University)H-Index: 60
view all 10 authors...
162 CitationsSource
Cited By2
Newest
#1Yijun Jia (Tongji University)H-Index: 11
#2Sha Zhao (Tongji University)H-Index: 14
Last. Caicun Zhou (Tongji University)H-Index: 68
view all 12 authors...
Abstract Objectives EGFR-targeted tyrosine kinase inhibitors (TKIs) have been the standard treatment for non-small cell lung cancer patients with EGFR mutations. However, most patients eventually develop resistance. With the development of immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD-1/PD-L1), there is a growing interest in developing combination strategies. However, there are concerns that the combination of a PD-(L)1 inhibitor and EGFR-TKI may be assoc...
8 CitationsSource
#1Weili Xue (Zhengzhou University)H-Index: 7
#2Weiming Li (Zhengzhou University)H-Index: 3
Last. Mingzhi Zhang (Zhengzhou University)H-Index: 23
view all 10 authors...
Purpose: NK/T-cell neoplasms are rare, highly aggressive, and insensitive to chemotherapy. These lymphomas have a poor prognosis, with patients being vulnerable to relapse. Hence, there is a need for alternative treatments. The purpose of this study is to investigate whether anti-PD1 takes effect on NK/T cell lymphoma. Methods: The expression of PD-L1 in NK/T cell lines was investigated by flow cytometry and by Western blot. In vivo, overall survival and median survival time of mice bearing an N...
12 CitationsSource